Abstract:Chimeric antigen receptor (CAR) T-cell therapy entails the genetic engineering of a patient's T-cells to express membrane spanning fusion receptors with defined specificities for tumor-associated antigens. These CARs are capable of eliciting robust T-cell activation to initiate killing of the target tumor cells. This therapeutic approach has produced unprecedented clinical outcomes in the treatment of "liquid" hematologic cancers, but to date has not produced comparable responses in targeting solid malignancies. Advances in our understanding of the immunobiology of solid tumors have highlighted several hurdles which currently hinder the efficacy of this therapy. These barriers include the insufficient accumulation of CAR T-cells in the tumor due to poor trafficking or physical exclusion and the exposure of infiltrating CAR T-cells to a panoply of immune suppressive checkpoint molecules, cytokines, and metabolic stresses that are not conducive to efficient immune reactions and can thereby render these cells anergic, exhausted, or apoptotic. This mini-review summarizes these hurdles and describes some recent approaches and innovations to genetically re-engineer CAR T-cells to counter inhibitory influences found in the tumor microenvironment. Novel immunotherapy drug combinations to potentiate the activity of CAR T-cells are also discussed. As our understanding of the immune landscape of tumors improves and our repertoire of immunotherapeutic drugs expands, it is envisaged that the efficacy of CAR T-cells against solid tumors might be potentiated using combination therapies, which it is hoped may lead to meaningful improvements in clinical outcome for patients with refractory solid malignancies.

Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors

Chimeric Antigen Receptor Natural Killer Cells: a Promising Antitumor Immunotherapy

Chimeric Antigen Receptor T Cells Applied to Solid Tumors

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

Current Progress in Chimeric Antigen Receptor T‐cell Therapy for Malignant Tumors

Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities.

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

Chimeric Antigen Receptor-T Cell Therapy for Solid Tumors Require New Clinical Regimens

A long way to the battlefront: CAR T cell therapy against solid cancers.

Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances

Hurdles of CAR-T Cell-Based Cancer Immunotherapy Directed Against Solid Tumors.

Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors

Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors

The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors

Challenges and interventions of chimeric antigen receptor-T cell therapy in solid tumors

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Current Challenges and Strategies for Chimeric Antigen Receptor-T-Cell Therapy for Solid Tumors

Prospects and challenges for use of CAR T cell therapies in solid tumors

Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities

Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)

New Chimeric Antigen Receptor Design for Solid Tumors